{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:36:20Z","timestamp":1794357380275,"version":"4.9.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41581-025-01008-2","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:37:25Z","timestamp":1759855045000},"page":"69-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Urine as a source of biomarkers and biological knowledge in chronic kidney disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-5713","authenticated-orcid":false,"given":"Antonia","family":"Vlahou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-1636","authenticated-orcid":false,"given":"Raymond","family":"Vanholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"1008_CR1","doi-asserted-by":"crossref","unstructured":"Chapter 1: definition and classification of CKD. Kidney Int. Suppl. 3, 19\u201362 (2013).","DOI":"10.1038\/kisup.2012.64"},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.3390\/ijms25073678","volume":"25","author":"HD Rupprecht","year":"2024","unstructured":"Rupprecht, H. D. et al. Non-invasive biomarkers for risk prediction of chronic kidney diseases and assessment of kidney fibrosis. Int. J. Mol. Sci. 25, 3678 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1008_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.semnephrol.2021.09.003","volume":"41","author":"I Sandokji","year":"2021","unstructured":"Sandokji, I. & Greenberg, J. H. Plasma and urine biomarkers of CKD: a review of findings in the CKiD study. Semin. Nephrol. 41, 416\u2013426 (2021).","journal-title":"Semin. Nephrol."},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00467-017-3701-9","volume":"33","author":"JH Greenberg","year":"2018","unstructured":"Greenberg, J. H., Kakajiwala, A., Parikh, C. R. & Furth, S. Emerging biomarkers of chronic kidney disease in children. Pediatr. Nephrol. 33, 925\u2013933 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"1008_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/MNH.0000000000000735","volume":"30","author":"A Zabetian","year":"2021","unstructured":"Zabetian, A. & Coca, S. G. Plasma and urine biomarkers in chronic kidney disease: closer to clinical application. Curr. Opin. Nephrol. Hypertens. 30, 531\u2013537 (2021).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1008_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/10408363.2023.2178378","volume":"60","author":"L Ge","year":"2023","unstructured":"Ge, L., Liu, J., Lin, B. & Qin, X. Progress in understanding primary glomerular disease: insights from urinary proteomics and in-depth analyses of potential biomarkers based on bioinformatics. Crit. Rev. Clin. Lab. Sci. 60, 346\u2013365 (2023).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"1008_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1681\/ASN.2022010098","volume":"33","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Systematic review and meta-analysis of plasma and urine biomarkers for CKD outcomes. J. Am. Soc. Nephrol. 33, 1657\u20131672 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.3390\/ijms25063519","volume":"25","author":"L Catanese","year":"2024","unstructured":"Catanese, L. et al. Non-invasive biomarkers for diagnosis and risk prediction of glomerular diseases: a comprehensive review. Int. J. Mol. Sci. 25, 3519 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1008_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/biom14010137","volume":"14","author":"F Patera","year":"2024","unstructured":"Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D. & Reboldi, G. Kidney fibrosis and oxidative stress: from molecular pathways to new pharmacological opportunities. Biomolecules 14, 137 (2024).","journal-title":"Biomolecules"},{"key":"1008_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1159\/000531946","volume":"147","author":"AL Bullen","year":"2023","unstructured":"Bullen, A. L. et al. Markers of kidney tubule dysfunction and major adverse kidney events. Nephron 147, 713\u2013716 (2023).","journal-title":"Nephron"},{"key":"1008_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/10408363.2020.1723487","volume":"57","author":"J Kami\u0144ska","year":"2020","unstructured":"Kami\u0144ska, J., Dymicka-Piekarska, V., Tomaszewska, J., Matowicka-Karna, J. & Koper-Lenkiewicz, O. M. Diagnostic utility of protein to creatinine ratio (P\/C ratio) in spot urine sample within routine clinical practice. Crit. Rev. Clin. Lab. Sci. 57, 345\u2013364 (2020).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.ekir.2022.03.026","volume":"7","author":"Y Wen","year":"2022","unstructured":"Wen, Y. et al. Considerations in controlling for urine concentration for biomarkers of kidney disease progression after acute kidney injury. Kidney Int. Rep. 7, 1502\u20131513 (2022).","journal-title":"Kidney Int. Rep."},{"key":"1008_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/proteomes12030018","volume":"12","author":"A Elguoshy","year":"2024","unstructured":"Elguoshy, A. et al. Investigating and annotating the human peptidome profile from urine under normal physiological conditions. Proteomes 12, 18 (2024).","journal-title":"Proteomes"},{"key":"1008_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/1389201018666170601091205","volume":"18","author":"S-H Kim","year":"2017","unstructured":"Kim, S.-H. et al. Advantages and limitations of current biomarker research: from experimental research to clinical application. Curr. Pharm. Biotechnol. 18, 445\u2013455 (2017).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1008_CR15","first-page":"57","volume":"25","author":"J Jing","year":"2018","unstructured":"Jing, J. & Gao, Y. Urine biomarkers in the early stages of diseases: current status and perspective. Discov. Med. 25, 57 65 (2018).","journal-title":"Discov. Med."},{"key":"1008_CR16","first-page":"29","volume":"149","author":"P Villalvazo","year":"2025","unstructured":"Villalvazo, P., Villavicencio, C., Gonzalez de Rivera, M., Fernandez-Fernandez, B. & Ortiz, A. Systems biology and novel biomarkers for the early detection of diabetic kidney disease. Nephron 149, 29\u201335 (2025).","journal-title":"Nephron"},{"key":"1008_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000543640","volume":"149","author":"T McDonnell","year":"2025","unstructured":"McDonnell, T., Banks, R. E., Taal, M. W., Vuilleumier, N. & Kalra, P. A. Personalized care in CKD: moving beyond traditional biomarkers. Nephron 149, 339\u2013357 (2025).","journal-title":"Nephron"},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic, R. Z., Cox, E. J., Neumiller, J. J. & Tuttle, K. R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227\u2013244 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605\u2013628 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR20","doi-asserted-by":"publisher","first-page":"15166","DOI":"10.3390\/ijms232315166","volume":"23","author":"J Feng","year":"2022","unstructured":"Feng, J., Chen, Z., Liang, W., Wei, Z. & Ding, G. Roles of mitochondrial DNA damage in kidney diseases: a new biomarker. Int. J. Mol. Sci. 23, 15166 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1008_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12882-019-1549-x","volume":"20","author":"CC Chang","year":"2019","unstructured":"Chang, C. C. et al. Urinary cell-free mitochondrial and nuclear deoxyribonucleic acid correlates with the prognosis of chronic kidney diseases. BMC Nephrol. 20, 391 (2019).","journal-title":"BMC Nephrol."},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ndt\/gfx339","volume":"33","author":"PZ Wei","year":"2018","unstructured":"Wei, P. Z. et al. Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy. Nephrol. Dial. Transplant. 33, 784\u2013788 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.817","volume":"12","author":"W Lv","year":"2022","unstructured":"Lv, W. et al. Circle-Seq reveals genomic and disease-specific hallmarks in urinary cell-free extrachromosomal circular DNAs. Clin. Transl. Med. 12, e817 (2022).","journal-title":"Clin. Transl. Med."},{"key":"1008_CR24","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/genes14071367","volume":"14","author":"E Agborbesong","year":"2023","unstructured":"Agborbesong, E., Bissler, J. & Li, X. Liquid biopsy at the frontier of kidney diseases: application of exosomes in diagnostics and therapeutics. Genes 14, 1367 (2023).","journal-title":"Genes"},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"1041327","DOI":"10.3389\/fphar.2022.1041327","volume":"13","author":"M Tepus","year":"2023","unstructured":"Tepus, M., Tonoli, E. & Verderio, E. A. M. Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis. Front. Pharmacol. 13, 1041327 (2023).","journal-title":"Front. Pharmacol."},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000529709","volume":"9","author":"J Wen","year":"2023","unstructured":"Wen, J. et al. Exosomes in diabetic kidney disease. Kidney Dis. 9, 131\u2013142 (2023).","journal-title":"Kidney Dis."},{"key":"1008_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fimmu.2020.00943","volume":"11","author":"Y Lu","year":"2020","unstructured":"Lu, Y., Liu, D., Feng, Q. & Liu, Z. Diabetic nephropathy: perspective on extracellular vesicles. Front. Immunol. 11, 943 (2020).","journal-title":"Front. Immunol."},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.diabet.2018.08.004","volume":"45","author":"P Prabu","year":"2019","unstructured":"Prabu, P. et al. MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the \u2018Asian Indian phenotype\u2019. Diabetes Metab. 45, 276\u2013285 (2019).","journal-title":"Diabetes Metab."},{"key":"1008_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nep.13472","volume":"23","author":"Y Zuo","year":"2018","unstructured":"Zuo, Y. & Liu, Y. New insights into the role and mechanism of Wnt\/\u03b2-catenin signalling in kidney fibrosis. Nephrology 23, 38\u201343 (2018).","journal-title":"Nephrology"},{"key":"1008_CR30","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/fcp.13031","volume":"38","author":"S Saxena","year":"2024","unstructured":"Saxena, S., Dagar, N., Shelke, V., Puri, B. & Gaikwad, A. B. Wnt\/beta-catenin modulation: a promising frontier in chronic kidney disease management. Fundam. Clin. Pharmacol. 38, 1020\u20131030 (2024).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"1008_CR31","doi-asserted-by":"publisher","first-page":"2121929","DOI":"10.1080\/0886022X.2022.2121929","volume":"45","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Expression of urinary exosomal miRNA-615-3p and miRNA-3147 in diabetic kidney disease and their association with inflammation and fibrosis. Ren. Fail. 45, 2121929 (2023).","journal-title":"Ren. Fail."},{"key":"1008_CR32","doi-asserted-by":"publisher","first-page":"107480","DOI":"10.1016\/j.compbiomed.2023.107480","volume":"166","author":"Z Zhao","year":"2023","unstructured":"Zhao, Z. et al. Identification of urinary extracellular vesicles differentially expressed RNAs in diabetic nephropathy via whole-transcriptome integrated analysis. Comput. Biol. Med. 166, 107480 (2023).","journal-title":"Comput. Biol. Med."},{"key":"1008_CR33","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/07853890.2021.1912384","volume":"53","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. The ratio of urinary TREM-1\/TREM-2 mRNA expression in chronic kidney disease and renal fibrosis. Ann. Med. 53, 1010\u20131018 (2021).","journal-title":"Ann. Med."},{"key":"1008_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2424751","volume":"2019","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. Decreased expression of urinary mammalian target of rapamycin mRNA is related to chronic renal fibrosis in IgAN. Dis. Markers 2019, 2424751 (2019).","journal-title":"Dis. Markers"},{"key":"1008_CR35","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.3390\/diagnostics13193077","volume":"13","author":"R Thielemans","year":"2023","unstructured":"Thielemans, R. et al. Unveiling the hidden power of uromodulin: a promising potential biomarker for kidney diseases. Diagnostics 13, 3077 (2023).","journal-title":"Diagnostics"},{"key":"1008_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/ndt\/gft345","volume":"29","author":"S Yuhanna","year":"2014","unstructured":"Yuhanna, S. et al. Determination of uromodulin in human urine: influence of storage and processing. Nephrol. Dial. Transplant. 29, 136\u2013145 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41581-024-00881-7","volume":"20","author":"A Nanamatsu","year":"2024","unstructured":"Nanamatsu, A., de Ara\u00fajo, L., LaFavers, K. A. & El-Achkar, T. M. Advances in uromodulin biology and potential clinical applications. Nat. Rev. Nephrol. 20, 806\u2013821 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR38","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.2215\/CJN.03600318","volume":"13","author":"E Pivin","year":"2018","unstructured":"Pivin, E. et al. Uromodulin and nephron mass. Clin. J. Am. Soc. Nephrol. 13, 1556\u20131557 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.04230415","volume":"11","author":"M Pruijm","year":"2016","unstructured":"Pruijm, M. et al. Associations of urinary uromodulin with clinical characteristics and markers of tubular function in the general population. Clin. J. Am. Soc. Nephrol. 11, 70\u201380 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2215\/CJN.04770415","volume":"11","author":"S Troyanov","year":"2016","unstructured":"Troyanov, S. et al. Clinical, genetic, and urinary factors associated with uromodulin excretion. Clin. J. Am. Soc. Nephrol. 11, 62\u201369 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR41","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/BF00180026","volume":"71","author":"S Pfleiderer","year":"1993","unstructured":"Pfleiderer, S. et al. Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of \u03b11-microglobulin and Tamm-Horsfall protein. Clin. Investig. 71, 972\u2013977 (1993).","journal-title":"Clin. Investig."},{"key":"1008_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0891-6632(91)90037-P","volume":"5","author":"LB Zimmerhackl","year":"1991","unstructured":"Zimmerhackl, L. B. et al. Tamm-Horsfall-protein excretion as a marker of ascending limb transport indicates early renal tubular damage in diabetes mellitus type I. J. Diabetes Complicat. 5, 112\u2013114 (1991).","journal-title":"J. Diabetes Complicat."},{"key":"1008_CR43","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2013010019","volume":"24","author":"CM O\u2019Seaghdha","year":"2013","unstructured":"O\u2019Seaghdha, C. M. et al. Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J. Am. Soc. Nephrol. 24, 1880\u20131888 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1008_CR44","first-page":"1219","volume":"11","author":"J Song","year":"2019","unstructured":"Song, J. et al. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology. Am. J. Transl. Res. 11, 1219\u20131229 (2019).","journal-title":"Am. J. Transl. Res."},{"key":"1008_CR45","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cmet.2021.04.004","volume":"33","author":"Y Mori","year":"2021","unstructured":"Mori, Y. et al. KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab. 33, 1042\u20131061.e7 (2021).","journal-title":"Cell Metab."},{"key":"1008_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-018-0068-5","volume":"18","author":"BN Lambrecht","year":"2018","unstructured":"Lambrecht, B. N., Vanderkerken, M. & Hammad, H. The emerging role of ADAM metalloproteinases in immunity. Nat. Rev. Immunol. 18, 745\u2013758 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1008_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000313363","volume":"31","author":"HM Siragy","year":"2010","unstructured":"Siragy, H. M. & Carey, R. M. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am. J. Nephrol. 31, 541\u2013550 (2010).","journal-title":"Am. J. Nephrol."},{"key":"1008_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38507-w","volume":"13","author":"K Kosaki","year":"2023","unstructured":"Kosaki, K. et al. Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations. Sci. Rep. 13, 11518 (2023).","journal-title":"Sci. Rep."},{"key":"1008_CR49","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami, J. et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139, e840\u2013e878 (2019).","journal-title":"Circulation"},{"key":"1008_CR50","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00467-020-04541-3","volume":"35","author":"G Cara-Fuentes","year":"2020","unstructured":"Cara-Fuentes, G. et al. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse. Pediatr. Nephrol. 35, 1887\u20131896 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"1008_CR51","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ndt\/gfw214","volume":"31","author":"N Endo","year":"2016","unstructured":"Endo, N. et al. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol. Dial. Transplant. 31, 2023\u20132033 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR52","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.ekir.2020.08.001","volume":"5","author":"AMG Guerrico","year":"2020","unstructured":"Guerrico, A. M. G. et al. Urinary CD80 discriminates among glomerular disease types and reflects disease activity. Kidney Int. Rep. 5, 2021\u20132031 (2020).","journal-title":"Kidney Int. Rep."},{"key":"1008_CR53","doi-asserted-by":"publisher","first-page":"10470","DOI":"10.3390\/ijms241310470","volume":"24","author":"K Romejko","year":"2023","unstructured":"Romejko, K., Markowska, M. & Niemczyk, S. The review of current knowledge on neutrophil gelatinase-associated lipocalin (NGAL). Int. J. Mol. Sci. 24, 10470 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1008_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000507858","volume":"45","author":"P He","year":"2020","unstructured":"He, P. et al. Significance of neutrophil gelatinase-associated lipocalin as a biomarker for the diagnosis of diabetic kidney disease: a systematic review and meta-analysis. Kidney Blood Press. Res. 45, 497\u2013509 (2020).","journal-title":"Kidney Blood Press. Res."},{"key":"1008_CR55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00011-018-1200-5","volume":"68","author":"B Kaleta","year":"2019","unstructured":"Kaleta, B. The role of osteopontin in kidney diseases. Inflamm. Res. 68, 93\u2013102 (2019).","journal-title":"Inflamm. Res."},{"key":"1008_CR56","doi-asserted-by":"publisher","first-page":"730","DOI":"10.23876\/j.krcp.21.303","volume":"41","author":"H Kim","year":"2022","unstructured":"Kim, H. et al. Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression. Kidney Res. Clin. Pract. 41, 730\u2013740 (2022).","journal-title":"Kidney Res. Clin. Pract."},{"key":"1008_CR57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2215\/CJN.02780319","volume":"15","author":"R Malhotra","year":"2020","unstructured":"Malhotra, R. et al. Urine markers of kidney tubule cell injury and kidney function decline in sprint trial participants with CKD. Clin. J. Am. Soc. Nephrol. 15, 349\u2013358 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR58","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/annrheumdis-2019-216312","volume":"79","author":"K Vanarsa","year":"2020","unstructured":"Vanarsa, K. et al. Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Ann. Rheum. Dis. 79, 1349\u20131361 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1008_CR59","first-page":"11200167","volume":"14","author":"Y Shen","year":"2023","unstructured":"Shen, Y. et al. Urine L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multi-ethnicity. Front. Immunol. 14, 11200167 (2023).","journal-title":"Front. Immunol."},{"key":"1008_CR60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/bioengineering10040444","volume":"10","author":"R Novak","year":"2023","unstructured":"Novak, R., Salai, G., Hrkac, S., Vojtusek, I. K. & Grgurevic, L. Revisiting the role of NAG across the continuum of kidney disease. Bioengineering 10, 444 (2023).","journal-title":"Bioengineering"},{"key":"1008_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcell.2017.00114","volume":"5","author":"P Cocchiaro","year":"2017","unstructured":"Cocchiaro, P. et al. The multifaceted role of the lysosomal protease cathepsins in kidney disease. Front. Cell Dev. Biol. 5, 114 (2017).","journal-title":"Front. Cell Dev. Biol."},{"key":"1008_CR62","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2337\/dc21-2204","volume":"45","author":"CP Limonte","year":"2022","unstructured":"Limonte, C. P. et al. Urinary proteomics identifies cathepsin D as a biomarker of rapid eGFR decline in type 1 diabetes. Diabetes Care 45, 1416\u20131427 (2022).","journal-title":"Diabetes Care"},{"key":"1008_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/proteomes9030032","volume":"9","author":"L Catanese","year":"2021","unstructured":"Catanese, L. et al. A novel urinary proteomics classifier for non-invasive evaluation of interstitial fibrosis and tubular atrophy in chronic kidney disease. Proteomes 9, 32 (2021).","journal-title":"Proteomes"},{"key":"1008_CR64","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/biom13071093","volume":"13","author":"N Sparding","year":"2023","unstructured":"Sparding, N. et al. Unique biomarkers of collagen type III remodeling reflect different information regarding pathological kidney tissue alterations in patients with IgA nephropathy. Biomolecules 13, 1093 (2023).","journal-title":"Biomolecules"},{"key":"1008_CR65","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/ndt\/gfaa003","volume":"36","author":"SJ Schunk","year":"2021","unstructured":"Schunk, S. J., Speer, T., Petrakis, I. & Fliser, D. Dickkopf 3-a novel biomarker of the \u2018kidney injury continuum\u2019. Nephrol. Dial. Transplant. 36, 761\u2013767 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR66","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000524586","volume":"53","author":"C Cortvrindt","year":"2022","unstructured":"Cortvrindt, C., Speeckaert, R., Delanghe, J. R. & Speeckaert, M. M. Urinary epidermal growth factor: a promising \u2018Next Generation\u2019 biomarker in kidney disease. Am. J. Nephrol. 53, 372\u2013387 (2022).","journal-title":"Am. J. Nephrol."},{"key":"1008_CR67","doi-asserted-by":"publisher","first-page":"2256415","DOI":"10.1080\/0886022X.2023.2256415","volume":"45","author":"H Chen","year":"2023","unstructured":"Chen, H., Ni, L. & Wu, X. Performance of urinary vitamin D-binding protein in diabetic kidney disease: a meta-analysis. Ren. Fail. 45, 2256415 (2023).","journal-title":"Ren. Fail."},{"key":"1008_CR68","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1161\/CIRCRESAHA.123.321763","volume":"132","author":"G Glorieux","year":"2023","unstructured":"Glorieux, G., Nigam, S. K., Vanholder, R. & Verbeke, F. Role of the microbiome in gut-heart-kidney cross talk. Circ. Res. 132, 1064\u20131083 (2023).","journal-title":"Circ. Res."},{"key":"1008_CR69","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.2215\/CJN.02660221","volume":"16","author":"MH Rosner","year":"2021","unstructured":"Rosner, M. H. et al. Classification of uremic toxins and their role in kidney failure. Clin. J. Am. Soc. Nephrol. 16, 1918\u20131928 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamainternmed.2018.7980","volume":"179","author":"SS Waikar","year":"2019","unstructured":"Waikar, S. S. et al. Association of urinary oxalate excretion with the risk of chronic kidney disease progression. JAMA Intern. Med. 179, 542\u2013551 (2019).","journal-title":"JAMA Intern. Med."},{"key":"1008_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2023.110703","volume":"123","author":"L Moritz","year":"2024","unstructured":"Moritz, L. et al. A systematic review of metabolomic findings in adult and pediatric renal disease. Clin. Biochem. 123, 110703 (2024).","journal-title":"Clin. Biochem."},{"key":"1008_CR72","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s10157-022-02264-3","volume":"26","author":"K Kakeshita","year":"2022","unstructured":"Kakeshita, K. et al. Prognostic impact of urine cyclic AMP levels in patients with chronic kidney disease. Clin. Exp. Nephrol. 26, 1194\u20131199 (2022).","journal-title":"Clin. Exp. Nephrol."},{"key":"1008_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41608-0","volume":"9","author":"A Hesaka","year":"2019","unstructured":"Hesaka, A. et al. D-serine reflects kidney function and diseases. Sci. Rep. 9, 5104 (2019).","journal-title":"Sci. Rep."},{"key":"1008_CR74","doi-asserted-by":"publisher","first-page":"F590","DOI":"10.1152\/ajprenal.00301.2022","volume":"324","author":"EA Houske","year":"2023","unstructured":"Houske, E. A. et al. Metabolomic profiling to identify early urinary biomarkers and metabolic pathway alterations in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol. 324, F590\u2013F602 (2023).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1008_CR75","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1681\/ASN.0000000000000403","volume":"35","author":"W-J Yeo","year":"2024","unstructured":"Yeo, W.-J. et al. Serum and urine metabolites and kidney function. J. Am. Soc. Nephrol. 35, 1252\u20131265 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1008_CR76","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00592-023-02094-z","volume":"60","author":"C Shi","year":"2023","unstructured":"Shi, C. et al. Urinary metabolites associate with the presence of diabetic kidney disease in type 2 diabetes and mediate the effect of inflammation on kidney complication. Acta Diabetol. 60, 1199\u20131207 (2023).","journal-title":"Acta Diabetol."},{"key":"1008_CR77","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.34067\/KID.0000000000000158","volume":"4","author":"Y Kim","year":"2023","unstructured":"Kim, Y. et al. Urinary metabolite profile predicting the progression of CKD. Kidney360 4, 1048\u20131057 (2023).","journal-title":"Kidney360"},{"key":"1008_CR78","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1053\/j.ajkd.2024.03.028","volume":"84","author":"I Steinbrenner","year":"2024","unstructured":"Steinbrenner, I. et al. Associations of urine and plasma metabolites with kidney failure and death in a chronic kidney disease cohort. Am. J. Kidney Dis. 84, 469\u2013481 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"1008_CR79","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf, R. M. Biomarker definitions and their applications. Exp. Biol. Med. 243, 213\u2013221 (2018).","journal-title":"Exp. Biol. Med."},{"key":"1008_CR80","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/ndt\/gfaa208","volume":"36","author":"JV Norvik","year":"2021","unstructured":"Norvik, J. V. et al. Urinary excretion of epidermal growth factor and rapid loss of kidney function. Nephrol. Dial. Transplant. 36, 1882\u20131892 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR81","doi-asserted-by":"publisher","first-page":"100834","DOI":"10.1016\/j.xkme.2024.100834","volume":"6","author":"JG Amatruda","year":"2024","unstructured":"Amatruda, J. G. et al. Urine biomarkers of kidney tubule health and risk of incident CKD in persons without diabetes: the ARIC, MESA, and REGARDS studies. Kidney Med. 6, 100834 (2024).","journal-title":"Kidney Med."},{"key":"1008_CR82","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.kint.2017.01.007","volume":"91","author":"GM McMahon","year":"2017","unstructured":"McMahon, G. M. et al. Urinary metabolites along with common and rare genetic variations are associated with incident chronic kidney disease. Kidney Int. 91, 1426\u20131435 (2017).","journal-title":"Kidney Int."},{"key":"1008_CR83","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","volume":"8","author":"N Tofte","year":"2020","unstructured":"Tofte, N. et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 8, 301\u2013312 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1008_CR84","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1681\/ASN.2014050423","volume":"26","author":"JP Schanstra","year":"2015","unstructured":"Schanstra, J. P. et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J. Am. Soc. Nephrol. 26, 1999\u20132010 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1008_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2369-11-29","volume":"11","author":"S Andersen","year":"2010","unstructured":"Andersen, S., Mischak, H., Z\u00fcrbig, P., Parving, H.-H. & Rossing, P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 11, 29 (2010).","journal-title":"BMC Nephrol."},{"key":"1008_CR86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung, C. K. et al. The pathogenesis of IgA nephropathy and implications for treatment. Nat. Rev. Nephrol. 21, 9\u201323 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR87","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3390\/jcm11113173","volume":"11","author":"Y Fukao","year":"2022","unstructured":"Fukao, Y. et al. Galactose-deficient IgA1 as a candidate urinary marker of IgA nephropathy. J. Clin. Med. 11, 3173 (2022).","journal-title":"J. Clin. Med."},{"key":"1008_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1209394","volume":"14","author":"Q Zeng","year":"2023","unstructured":"Zeng, Q. et al. Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis. Front. Immunol. 14, 1209394 (2023).","journal-title":"Front. Immunol."},{"key":"1008_CR89","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/ndt\/gfad200","volume":"39","author":"E Mavrogeorgis","year":"2024","unstructured":"Mavrogeorgis, E. et al. Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease. Nephrol. Dial. Transplant. 39, 453\u2013462 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR90","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/ndt\/gfw337","volume":"32","author":"J Siwy","year":"2017","unstructured":"Siwy, J. et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol. Dial. Transplant. 32, 2079\u20132089 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR91","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/art.41507","volume":"73","author":"JM Mejia-Vilet","year":"2021","unstructured":"Mejia-Vilet, J. M. et al. Association between urinary epidermal growth factor and renal prognosis in lupus nephritis. Arthritis Rheumatol. 73, 244\u2013254 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1008_CR92","doi-asserted-by":"publisher","first-page":"935700","DOI":"10.3389\/fimmu.2022.935700","volume":"13","author":"YJ Huang","year":"2022","unstructured":"Huang, Y. J., Lin, C. H., Yang, H. Y., Luo, S. F. & Kuo, C. F. Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis. Front. Immunol. 13, 935700 (2022).","journal-title":"Front. Immunol."},{"key":"1008_CR93","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/ASN.2019121285","volume":"31","author":"JM Mejia-Vilet","year":"2020","unstructured":"Mejia-Vilet, J. M. et al. Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J. Am. Soc. Nephrol. 31, 1335\u20131347 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1008_CR94","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/ckj\/sfac257","volume":"16","author":"P Anton-Pampols","year":"2023","unstructured":"Anton-Pampols, P. et al. Combining neutrophil and macrophage biomarkers to detect active disease in ANCA vasculitis: a combinatory model of calprotectin and urine CD163. Clin. Kidney J. 16, 693\u2013700 (2023).","journal-title":"Clin. Kidney J."},{"key":"1008_CR95","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema, I. M. et al. Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National institutes of health activity and chronicity indices. Kidney Int. 93, 789\u2013796 (2018).","journal-title":"Kidney Int."},{"key":"1008_CR96","doi-asserted-by":"publisher","first-page":"117798","DOI":"10.1016\/j.cca.2024.117798","volume":"555","author":"E Canki","year":"2024","unstructured":"Canki, E., Kho, E. & Hoenderop, J. G. J. Urinary biomarkers in kidney disease. Clin. Chim. Acta 555, 117798 (2024).","journal-title":"Clin. Chim. Acta"},{"key":"1008_CR97","doi-asserted-by":"publisher","first-page":"104645","DOI":"10.1016\/j.ebiom.2023.104635","volume":"93","author":"F Bienaim\u00e9","year":"2023","unstructured":"Bienaim\u00e9, F. et al. Combining robust urine biomarkers to assess chronic kidney disease progression. EBioMedicine 93, 104645 (2023).","journal-title":"EBioMedicine"},{"key":"1008_CR98","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1373\/clinchem.2015.250993","volume":"62","author":"JL Carter","year":"2016","unstructured":"Carter, J. L. et al. Biological variation of plasma and urinary markers of acute kidney injury in patients with chronic kidney disease. Clin. Chem. 62, 876\u2013883 (2016).","journal-title":"Clin. Chem."},{"key":"1008_CR99","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.190304","author":"A Segarra","year":"2019","unstructured":"Segarra, A., et al. Analytical and biological variability of urinary epidermal growth factor-to-creatinine ratio in patients with chronic kidney disease and in healthy volunteers. Clin. Lab. https:\/\/doi.org\/10.7754\/Clin.Lab.2019.190304 (2019).","journal-title":"Clin. Lab."},{"key":"1008_CR100","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ndt\/gfx068","volume":"33","author":"E Critselis","year":"2018","unstructured":"Critselis, E., Vlahou, A., Stel, V. S. & Morton, R. L. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrol. Dial. Transplant. 33, 441\u2013449 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR101","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.kint.2017.11.024","volume":"93","author":"N Nowak","year":"2018","unstructured":"Nowak, N. et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 93, 1198\u20131206 (2018).","journal-title":"Kidney Int."},{"key":"1008_CR102","doi-asserted-by":"publisher","first-page":"958","DOI":"10.2215\/CJN.0000000711","volume":"20","author":"SJ Schrauben","year":"2025","unstructured":"Schrauben, S. J. et al. Urine biomarkers for diabetic kidney disease progression in participants of the chronic renal insufficiency cohort study. Clin. J. Am. Soc. Nephrol. 20, 958\u2013967 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186836","volume":"10","author":"CL Tamargo","year":"2025","unstructured":"Tamargo, C. L. et al. The distal nephron biomarkers associate with diabetic kidney disease progression. JCI Insight 10, e186836 (2025).","journal-title":"JCI Insight"},{"key":"1008_CR104","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.kint.2023.08.007","volume":"104","author":"S Menez","year":"2023","unstructured":"Menez, S. et al. The ASSESS-AKI study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events. Kidney Int. 104, 1194\u20131205 (2023).","journal-title":"Kidney Int."},{"key":"1008_CR105","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/biom12091280","volume":"12","author":"SH Suh","year":"2022","unstructured":"Suh, S. H. et al. Urinary angiotensinogen and progression of chronic kidney disease: results from KNOW-CKD study. Biomolecules 12, 1280 (2022).","journal-title":"Biomolecules"},{"key":"1008_CR106","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1681\/ASN.2018040405","volume":"29","author":"S Zewinger","year":"2018","unstructured":"Zewinger, S. et al. Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J. Am. Soc. Nephrol. 29, 2722\u20132733 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1008_CR107","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ki.2015.192","volume":"88","author":"PS Garimella","year":"2015","unstructured":"Garimella, P. S. et al. Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults. Kidney Int. 88, 1126\u20131134 (2015).","journal-title":"Kidney Int."},{"key":"1008_CR108","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1159\/000528918","volume":"53","author":"TK Chen","year":"2022","unstructured":"Chen, T. K. et al. Urinary biomarkers of tubular health and risk for kidney function decline or mortality in diabetes. Am. J. Nephrol. 53, 775\u2013785 (2022).","journal-title":"Am. J. Nephrol."},{"key":"1008_CR109","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2016.09.003","volume":"91","author":"C-Y Hsu","year":"2017","unstructured":"Hsu, C.-Y. et al. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int. 91, 196\u2013203 (2017).","journal-title":"Kidney Int."},{"key":"1008_CR110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139927","volume":"131","author":"J Puthumana","year":"2021","unstructured":"Puthumana, J. et al. Biomarkers of inflammation and repair in kidney disease progression. J. Clin. Invest. 131, e139927 (2021).","journal-title":"J. Clin. Invest."},{"key":"1008_CR111","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167731","volume":"8","author":"Y Wen","year":"2023","unstructured":"Wen, Y. et al. Longitudinal biomarkers and kidney disease progression after acute kidney injury. JCI Insight 8, e167731 (2023).","journal-title":"JCI Insight"},{"key":"1008_CR112","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa307","volume":"37","author":"M Rudnicki","year":"2021","unstructured":"Rudnicki, M. et al. Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrol. Dial. Transplant. 37, 42\u201352 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR113","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1093\/ndt\/gfad125","volume":"38","author":"B Peters","year":"2023","unstructured":"Peters, B. et al. Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. Nephrol. Dial. Transplant. 38, 2826\u20132834 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR114","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2215\/CJN.0000000676","volume":"20","author":"V-G Peschard","year":"2025","unstructured":"Peschard, V.-G. et al. Defining kidney health dimensions and their associations with adverse outcomes in persons with diabetes and chronic kidney disease. Clin. J. Am. Soc. Nephrol. 20, 665\u2013675 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1008_CR115","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1053\/j.ajkd.2021.01.018","volume":"78","author":"I Steinbrenner","year":"2021","unstructured":"Steinbrenner, I. et al. Urine metabolite levels, adverse kidney outcomes, and mortality in CKD patients: a metabolome-wide association study. Am. J. Kidney Dis. 78, 669\u2013677.e1 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1008_CR116","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000521940","volume":"53","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. High-throughput metabolomics and diabetic kidney disease progression: evidence from the chronic renal insufficiency (CRIC) study. Am. J. Nephrol. 53, 215\u2013225 (2022).","journal-title":"Am. J. Nephrol."},{"key":"1008_CR117","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170341","volume":"133","author":"K Sharma","year":"2023","unstructured":"Sharma, K. et al. Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients. J. Clin. Invest. 133, e170341 (2023).","journal-title":"J. Clin. Invest."},{"key":"1008_CR118","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/dom.14779","volume":"24","author":"T Sen","year":"2022","unstructured":"Sen, T. et al. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: a post hoc mediation analysis of the CANVAS trial. Diabetes Obes. Metab. 24, 1950\u20131956 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"1008_CR119","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cpt.3237","volume":"115","author":"J Cho","year":"2024","unstructured":"Cho, J. et al. Dapagliflozin reduces urinary kidney injury biomarkers in chronic kidney disease irrespective of albuminuria level. Clin. Pharmacol. Ther. 115, 1441\u20131449 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1008_CR120","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/ndt\/gfad223","volume":"39","author":"MA Jaimes Campos","year":"2024","unstructured":"Jaimes Campos, M. A. et al. Urinary peptide analysis to predict the response to blood pressure medication. Nephrol. Dial. Transplant. 39, 873\u2013883 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000529374","volume":"54","author":"KR Tuttle","year":"2023","unstructured":"Tuttle, K. R. et al. Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide. Am. J. Nephrol. 54, 74\u201382 (2023).","journal-title":"Am. J. Nephrol."},{"key":"1008_CR122","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04258397 (2022)."},{"key":"1008_CR123","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1093\/ndt\/gfw292","volume":"32","author":"M Lindhardt","year":"2017","unstructured":"Lindhardt, M. et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-protect 2 study. Nephrol. Dial. Transplant. 32, 1866\u20131873 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1008_CR124","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","volume":"9","author":"DM Good","year":"2010","unstructured":"Good, D. M. et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteom. 9, 2424\u20132437 (2010).","journal-title":"Mol. Cell. Proteom."},{"key":"1008_CR125","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036637","volume":"13","author":"D Pieper","year":"2024","unstructured":"Pieper, D. et al. Urinary Dickkopf-3 as a potential marker for estimated glomerular filtration rate decline in patients with heart failure. J. Am. Heart Assoc. 13, e036637 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1008_CR126","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","volume":"402","author":"D van Mil","year":"2023","unstructured":"van Mil, D. et al. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet 402, 1052\u20131064 (2023).","journal-title":"Lancet"},{"key":"1008_CR127","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1053\/j.ajkd.2021.01.009","volume":"78","author":"LM Miller","year":"2021","unstructured":"Miller, L. M. et al. Association of urine biomarkers of kidney tubule injury and dysfunction with frailty index and cognitive function in persons with CKD in SPRINT. Am. J. Kidney Dis. 78, 530\u2013540.e1 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1008_CR128","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1053\/j.ajkd.2020.03.015","volume":"76","author":"JB Scheppach","year":"2020","unstructured":"Scheppach, J. B. et al. Albuminuria and estimated GFR as risk factors for dementia in midlife and older age: findings from the ARIC study. Am. J. Kidney Dis. 76, 775\u2013783 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1008_CR129","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nbt.3912","volume":"35","author":"KA Phillips","year":"2017","unstructured":"Phillips, K. A. et al. Payer coverage policies for multigene tests. Nat. Biotechnol. 35, 614\u2013617 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1008_CR130","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fpubh.2019.00042","volume":"7","author":"GA Bilkey","year":"2019","unstructured":"Bilkey, G. A. et al. Optimizing precision medicine for public health. Front. Public. Health 7, 42 (2019).","journal-title":"Front. Public. Health"},{"key":"1008_CR131","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jval.2018.06.011","volume":"21","author":"JR Trosman","year":"2018","unstructured":"Trosman, J. R. et al. From the past to the present: insurer coverage frameworks for next-generation tumor sequencing. Value Health 21, 1062\u20131068 (2018).","journal-title":"Value Health"},{"key":"1008_CR132","first-page":"qxad005","volume":"1","author":"JR Trosman","year":"2023","unstructured":"Trosman, J. R. et al. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Aff. Sch. 1, qxad005 (2023).","journal-title":"Health Aff. Sch."},{"key":"1008_CR133","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2020.7542","volume":"18","author":"MP Douglas","year":"2020","unstructured":"Douglas, M. P., Gray, S. W. & Phillips, K.A. Private payer and Medicare coverage for circulating tumor DNA testing: a historical analysis of coverage policies from 2015 to 2019. J. Natl Compr. Cancer Netw. 18, 866\u2013872 (2020).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1008_CR134","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/HYPERTENSIONAHA.120.16340","volume":"77","author":"A Vlahou","year":"2021","unstructured":"Vlahou, A. et al. Data sharing under the general data protection regulation: time to harmonize law and research ethics? Hypertension 77, 1029\u20131035 (2021).","journal-title":"Hypertension"},{"key":"1008_CR135","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41581-024-00828-y","volume":"20","author":"C Zoccali","year":"2024","unstructured":"Zoccali, C. et al. A new era in the science and care of kidney diseases. Nat. Rev. Nephrol. 20, 460\u2013472 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR136","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41581-023-00745-6","volume":"19","author":"R Vanholder","year":"2023","unstructured":"Vanholder, R. et al. Inequities in kidney health and kidney care. Nat. Rev. Nephrol. 19, 694\u2013708 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR137","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1515\/cclm-2019-0098","volume":"57","author":"A Kluytmans","year":"2019","unstructured":"Kluytmans, A. et al. Clinical biomarker innovation: when is it worthwhile? Clin. Chem. Lab. Med. 57, 1712\u20131720 (2019).","journal-title":"Clin. Chem. Lab. Med."},{"key":"1008_CR138","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12962-018-0105-z","volume":"16","author":"G de Graaf","year":"2018","unstructured":"de Graaf, G., Postmus, D., Westerink, J. & Buskens, E. The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. Cost. Eff. Resour. Alloc. 16, 23 (2018).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"1008_CR139","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.kint.2024.01.012","volume":"105","author":"A Reznichenko","year":"2024","unstructured":"Reznichenko, A. et al. Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine. Kidney Int. 105, 1263\u20131278 (2024).","journal-title":"Kidney Int."},{"key":"1008_CR140","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41581-025-00961-2","volume":"21","author":"SR Madhvapathy","year":"2025","unstructured":"Madhvapathy, S. R. et al. Implantable bioelectronics and wearable sensors for kidney health and disease. Nat. Rev. Nephrol. 21, 443\u2013463 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1008_CR141","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41581-025-00931-8","volume":"21","author":"MF Blum","year":"2025","unstructured":"Blum, M. F., Neuen, B. L. & Grams, M. E. Risk-directed management of chronic kidney disease. Nat. Rev. Nephrol. 21, 287\u2013298 (2025).","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01008-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:02:24Z","timestamp":1765890144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01008-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01008-2","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"4 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}